Gene Transfer to the CNS Is Efficacious in Immune-primed Mice Harboring Physiologically Relevant Titers of Anti-AAV Antibodies
| Autor: | S. Pablo Sardi, Marco A. Passini, Jie Bu, Lisa Woodworth, Gregory D Hurlbut, James Dodge, Lamya S. Shihabuddin, Christopher M. Treleaven, Thomas J. Tamsett, Jonathan A. Fidler, Seng H. Cheng |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Transgene Genetic enhancement Genetic Vectors Gene delivery Biology Antibodies Viral Mice Immune system Immunity Drug Discovery Genetics Animals Humans Transgenes Molecular Biology Neuroinflammation Pharmacology Gene Transfer Techniques Antibody titer Brain Genetic Therapy Dependovirus Niemann-Pick Disease Type A Virology Disease Models Animal Immunology biology.protein Molecular Medicine Original Article Immunization Antibody Biomarkers |
| Zdroj: | Molecular Therapy. 20(9):1713-1723 |
| ISSN: | 1525-0016 |
| DOI: | 10.1038/mt.2012.114 |
| Popis: | Central nervous system (CNS)-directed gene therapy with recombinant adeno-associated virus (AAV) vectors has been used effectively to slow disease course in mouse models of several neurodegenerative diseases. However, these vectors were typically tested in mice without prior exposure to the virus, an immunological scenario unlikely to be duplicated in human patients. Here, we examined the impact of pre-existing immunity on AAV-mediated gene delivery to the CNS of normal and diseased mice. Antibody levels in brain tissue were determined to be 0.6% of the levels found in systemic circulation. As expected, transgene expression in brains of mice with relatively high serum antibody titers was reduced by 59–95%. However, transduction activity was unaffected in mice that harbored more clinically relevant antibody levels. Moreover, we also showed that markers of neuroinflammation (GFAP, Iba1, and CD3) and histopathology (hematoxylin and eosin (H&E)) were not enhanced in immune-primed mice (regardless of pre-existing antibody levels). Importantly, we also demonstrated in a mouse model of Niemann Pick Type A (NPA) disease that pre-existing immunity did not preclude either gene transfer to the CNS or alleviation of disease-associated neuropathology. These findings support the continued development of AAV-based therapies for the treatment of neurological disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|